EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Human NKG2C+ adaptive NK cells for Cancer immunotherapy

Qiao Tang, Zhigang Tian, Jiacheng Bi

International Immunopharmacology · 2026-10 · 186 · 117160

DOI: 10.1016/j.intimp.2026.117160 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-10. Verfasst von Qiao Tang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen 518055, China; Faculty of Synthetic Biology, Shenzhen U…. Hauptthemen laut MEDLINE: Killer Cells, Natural, NK Cell Lectin-Like Receptor Subfamily C, Neoplasms, Immunotherapy. Die Arbeit nennt 109 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cells are key components of the innate immune system and play a pivotal role in tumor immunosurveillance. In recent years, a subset of NKG2C+ adaptive NK cells induced by human cytomegalovirus (HCMV) infection has attracted considerable attention because of its distinctive memory-like properties. This subset has shown substantial therapeutic potential in preclinical models of both haematological malignancies and solid tumors, and early-phase clinical trials in acute myeloid leukaemia (AML) and ovarian cancer have indicated a favorable safety profile with preliminary signs of efficacy. By applying a "super-donor" selection strategy and combining NKG2C-specific activation with cytokine stimulation, efficient ex vivo expansion of NKG2C+ adaptive NK cells can be achieved. When further integrated with synthetic immunology approaches-such as NK cell engagers (NKCEs) or engineered receptors-together with epigenetic modulation and metabolic reprogramming, the antitumor functions of this subset can be comprehensively augmented. These advances may unlock its therapeutic potential and offer new directions and paradigms for next-generation cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalNK Cell Lectin-Like Receptor Subfamily CNeoplasmsImmunotherapyImmunotherapy, AdoptiveHumansAnimalsAdaptive ImmunityCytomegalovirus InfectionsCytomegalovirus

Stichwörter der Autor:innen

HCMVHuman NKG2C(+) adaptive NK cellsImmunotherapyNKG2C/CD94

Substanzen

NK Cell Lectin-Like Receptor Subfamily CKLRC2 protein, human

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen 518055, China; Faculty of Synthetic Biology, Shenzhen University of Advanced Technology, Shenzhen 518107, China; State Key La…
  • State Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; State Key Laboratory of I…
  • Faculty of Synthetic Biology, Shenzhen University of Advanced Technology, Shenzhen 518107, China; State Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of A…

Förderung

  • Shenzhen Science and Technology Innovation Program
  • National Natural Science Foundation of China

Zitieren

APA

Tang, Q., Tian, Z., & Bi, J. (2026). Human NKG2C+ adaptive NK cells for Cancer immunotherapy. International Immunopharmacology, 186, 117160. https://doi.org/10.1016/j.intimp.2026.117160

Vancouver

Tang Q, Tian Z, Bi J. Human NKG2C+ adaptive NK cells for Cancer immunotherapy. International Immunopharmacology. 2026;186:117160. doi:10.1016/j.intimp.2026.117160

BibTeX
@article{Tang2026,
  author = {Tang, Qiao and Tian, Zhigang and Bi, Jiacheng},
  title = {Human NKG2C+ adaptive NK cells for Cancer immunotherapy},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {186},
  pages = {117160},
  doi = {10.1016/j.intimp.2026.117160}
}
Kostenlos starten →